News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xenogen Biosciences Announces Target Validation Collaboration Agreement With Schering-Plough Corporation (SGP)


8/17/2006 11:36:14 AM

HOPKINTON, Mass., Aug. 17 /PRNewswire-FirstCall/ -- Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. (Nasdaq: CALP - News), today announced a target validation collaboration with Schering-Plough Corporation (NYSE: SGP - News), under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high value targets resulting from drug discovery research conducted by the Schering-Plough Research Institute.

SPCT evaluates the physiological and behavioral impact of such high value targets by utilizing a battery of more than 85 pharmacologically-validated challenge or bioassays (measuring over 400 individual parameters), and covering most therapeutic areas. The recently signed phenotypic characterization agreement expands on a previous gene targeting agreement aimed at the creation of standard and conditional gene knockouts, both of which contribute to a fuller understanding of the biological effects associated with the deletion of a gene's function. Financial terms of the deal were not disclosed.

About Xenogen Biosciences

Xenogen Biosciences, now Caliper Life Sciences, offers more than 15 years of experience in the transgenic and gene knockout field. The company has completed more than 2,500 transgenic and 800 gene targeting projects, with a greater than 97 percent success rate in delivering transgenic founder or gene knockout lines to customers. Additionally, the company now offers its SPCT technology and In Vivo Compound Profiling, a comprehensive efficacy platform used to confirm and/or discover new or secondary indications.

About Caliper Life Sciences

Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its recent acquisitions of NovaScreen Biosciences and Xenogen Corp., Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper's products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at www.caliperLS.com.

NOTE: Caliper is a registered trademark of Caliper Life Sciences, Inc.

Source: Caliper Life Sciences

>>> Discuss This Story


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES